LifT BioSciences has attracted an impressive line-up of cornerstone investors for its next funding round, which will allow the company to conduct its forthcoming Proof of Concept trial and bioreactor scale-up.
Amongst the lead investors is a very well know Biotech Angel and the company is also in detailed discussions with a major pharmaceutical company, as it seeks co-development partners.
Current Shadow Foundr investors have invested in LifT BioSciences at pre-money valuation of £6 million. LifT BioSciences has received Letters of Intent for follow on institutional funding of up to £7 million at a starting pre-money valuation of £11 million including, which is great news for Shadow Foundr investors.
LIfT Biosciences is a Biotech bringing to market a first in class Immuno-Oncology Cell Therapy called N-LIfT that has the game-changing potential to destroy all solid tumours irrespective of mutation or strain.
N-LIfT (Neutrophil Only Leukocyte Infusion Therapy) builds on 18 years of ground-breaking research into innate cancer immunity by the renown co-founder Prof Zheng Cui.
LIfT has already proven to be 100% curative in mice and with promising human data in an FDA approved safety trial showing up to 80% tumour necrosis in a mix of late stage carcinoma patients even at low dose.
The Company’s vision is to develop the world’s first cell bank of ‘cancer killing neutrophils’ to deliver a portfolio of immuno-oncology cell therapies for all solid tumours, with an initial focus on high unmet need orphan tumours such as those found in the lung, liver and pancreas.